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Background/Aims
Recent studies reveal that acute gastroenteritis can precipitate irritable bowel syndrome (IBS) symptoms leading to the concept 
of post-infectious IBS. However, the overall contribution of gastroenteritis to the total IBS prevalence is unknown. In this ex-
ercise we try to estimate the contribution of gastroenteritis in IBS using the published literature and a longitudinal approach.
Methods
Existing literature was reviewed to determine the incidence of IBS after gastroenteritis, the rate of remission over time, data 
on rates of gastroenteritis in a given population and any patterns of resistance to these effects in human populations. This 
produced 3 models. The first assumed all humans were susceptible to gastroenteritis and its ability to produce IBS. The second 
assumed (using meta-analysis data) that 90% of humans in a given outbreak would be resistant to this effect. The third model 
used a high gastroenteritis exposure rate as might be seen in military deployment. 
Results 
In model 1, the prevalence was unrealistically high with an eventual steady state of 43.6% of the population affected by IBS. 
In a very conservative approach (model 2), steady state was achieved after 10 years to an overall prevalence of 8.9%. 
Interestingly, based on a high 1 year exposure rate such as military deployment, the maximum prevalence (steady state) was 
reached before 1 year suggesting high risk.
Conclusions
Although hypothetical in approach, based on conservative estimates in existing literature the contribution of gastroenteritis to 
the overall prevalence of IBS is substantial. 
(J Neurogastroenterol Motil 2012;18:200-204)
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Introduction
Irritable bowel syndrome (IBS) is a common and debilitating 
disease process, yet the precise pathophysiology of IBS remains 
unknown. In recent years, data are continuing to accumulate 
which suggest that gut bacteria play a role in IBS symptom 
development. In one bacterial hypothesis, it is suggested that 
there is an altered distribution of bacteria in the gut.1,2 A second 
bacterial hypothesis suggests that IBS arises from an episode of 
acute gastroenteritis involving a viral, bacterial or other infection 
in a susceptible host. Two meta-analyses of the studies to date 
found that approximately 10% of subjects who experience acute 
gastroenteritis subsequently develop IBS.3,4 Of note, many of the 
specific pathogens which have been shown to increase the risk of 
post-infectious IBS (PI-IBS) are also common among domes-
tically acquired infections (eg, Campylobacter and Salmonella).
While these meta-analyses provide convincing evidence that 
acute gastroenteritis can precipitate IBS, the overall contribution 
of acute gastroenteritis to the total IBS population in the United 
States (US) is unknown. Large prospective observational studies 
could be conducted to precisely define the contribution of acute 
gastroenteritis to the burden of IBS in the community. However, 
these types of studies would be difficult to design and expensive to 
attempt at this time. Despite these challenges, determining the 
contribution of acute gastroenteritis to development of IBS in the 
population as a whole would be vital to understanding implications 
in long-term health care cost, impact on food and water safety poli-
cies, and even impact on missionary or military deployment policy. 
Therefore, to raise awareness to this novel hypothesis, we de-
scribe a basic and empiric population-based approach to illustrate 
the theoretical extent to which acute gastroenteritis could contrib-
ute to the development of IBS over time, based on the existing lit-
erature surrounding PI-IBS. 
Materials and Methods
To estimate the population-attributable fraction of IBS due 
to a post-infectious etiology, we employed an empiric steady-state 
model based on factors of population dynamics, infectious disease 
incidence, PI-IBS risk, and characteristics of IBS illness and du-
ration derived from currently available published literature. 
Where uncertainty existed, the most conservative estimate was 
utilized. The following assumptions and parameter estimates 
were utilized to support the development of 3 models:
(1) The US population remained 307,000,000.5 
(2) The incidence rate of infectious gastroenteritis was 76 
million (24.76%) annually6 among the US population 
and was not affected by age.
(3) The incidence rate of IBS was 10% among those who 
contracted acute gastroenteritis.3,4
(4) Fifty-eight percent of IBS patients went into complete re-
mission after 6 years7 but were then eligible to re-contract 
new IBS through a new acute gastroenteritis event.
(5) The remaining 42% of IBS patients remained sympto-
matic throughout their life and were replaced by un-
affected individuals at death.
(6) A lifetime of IBS was calculated as US life expectancy (78 
years) less the average age of IBS onset (29 years), since 
the age distribution of IBS was assumed to be similar to 
that of the overall US age distribution.
(7) Episodes of acute gastroenteritis occurred at some point 
during the year.
(8) IBS was contracted at year’s end and could resolve at the 
beginning of any given year.
Model 1: All Individuals in the Population 
Were Equally at Risk for Development of 
Irritable Bowel Syndrome
We applied the model to a population that was initially un-
affected by acute gastroenteritis or IBS, and the model was run 
iteratively for a number of years. The assumption in this model 
was that all humans had the potential to develop IBS and that 
there was no genetic, host or environmental resistance to this 
outcome. The model is as follows:
pyear n = 
    ×× ×     ×

 
 

    ×× × ××
 


    ××
n = the year during which each incremental annual IBS 
prevalence is calculated, beginning at year zero and increased by 
one until steady-state is reached (when incremental annual IBS 
prevalence does not change).
p = the IBS prevalence at the end of the year for which the 
above equation was calculated (beginning with pyear 0 = 0). 
t = the total US population at risk to contract IBS 
(307,000,000)
T = the total US population (307,000,000)
rAGE = the annual incidence of acute gastroenteritis (24.76%)
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rIBS = a person’s chance of contracting IBS given a case of 
gastroenteritis during the year for which the equation is being run 
(10%)
s = the published remission rate of IBS at a 6 year follow-up 
(58%)

 
 

    ×× × ××
 


The amortization portion of the expression above functions 
to account for the published IBS remission rate at a 6 year fol-
low-up. The 58% remission was amortized equally over the 6 
years prior. 
pyear n-50×T×(1－s)
The above component accounts for patients with lifetime IBS 
who lose their disease state due to death and are replaced by per-
sons of average age who are re-eligible to contract IBS. To ac-
complish this, the expression becomes relevant once n equals 50 
(78 year lifespan, less age 29 average onset of IBS, plus one to ac-
count for IBS starting at the beginning of age 29).
Model 2: Only a Minority of Subjects in the 
Population Could Develop Irritable Bowel Syn-
drome After Gastroenteritis 
A major drawback of Model 1 was the assumption of equal 
risk of IBS development among individuals. Recent data sug-
gests that there could be genetic pre-determinants to suscepti-
bility of PI-IBS.8 This is supported by the fact that in previous 
meta-analyses,3,4 only 10% of subjects who experienced con-
firmed gastroenteritis actually developed IBS. Therefore, in this 
model, the conservative assumption was made that only 10% of 
the infected population was susceptible to developing IBS. In es-
sence, 90% of the population in this model had innate resistance 
by some mechanism.
For Model 2, the following modifications are made to the as-
sumptions in model 1. Model 1 was designed without any genetic 
susceptibility, and therefore rIBS was set at 10% to represent the 
equal chance of contracting IBS among all 76 million individuals 
who suffered gastroenteritis in a given year. We have built Model 
2 to represent the other extreme of genetic susceptibility. We 
modified t such that the total US population eligible to contract 
IBS is only 30,700,000 (10% of the total US population). In ad-
dition, we set rIBS at 100% such that genetically susceptible in-
dividuals would definitely contract IBS if they experienced 
gastroenteritis. In both models, 10% of the overall 307 million 
would be eligible to develop IBS from an initial episode of 
gastroenteritis. However, in Model 2, the other 90% of the pop-
ulation could still contract gastroenteritis but would be unable to 
contract IBS due to lack of genetic susceptibility. The denomi-
nator of the equation (T) remains 307 million to account for a 
prevalence calculation based on the entire US population. rIBS is 
increased to 100% and therefore becomes irrelevant to Model 2, 
since a person with gastroenteritis will contract IBS if they are ge-
netically predisposed to doing so.
Model 3: Assuming a Population With High 
Incidence of Infectious Gastroenteritis
Certain individuals, such as active-duty military personnel 
and religious missionaries, are more prone to developing acute 
gastroenteritis than those from the regular population. To portray 
findings among high-risk groups, we applied our previous model 
of varied individual predisposition to IBS (Model 2) to an ac-
tive-duty military population whose characteristics were based on 
data from US. Military deployment studies. In contrast to our 
normal population in Model 2, the proportion of active-duty in-
dividuals who develop acute gastroenteritis was 29% per month.9 
We assumed a wartime deployment pattern with a typical initial 
deployment period of 12 months to a high-risk zone. We then si-
mulated a return to a normal-risk area for the following 9 years.
For model 3, the first year of the model is calculated on a 
monthly basis using the monthly incidence rate of 29% 
(represented by rAGE in high-risk environment) over 12 months from month 
m = 0 through m = 11. As in Model 2, rIBS remains 100% and 
was therefore irrelevant to this model as well.
pmonth m = 
(t-pmonth m-1×T)×rAGE in high-risk environment+pmonth m-1×T
T
 pyear 0 = pmonth11
Subsequent years of the simulation, beginning with pyear 1, 
were run using the equation and assumptions from model 2.
Results
Figures 1, 2 and 3 demonstrate the effects of the different 
models. Interestingly, Model 1 (Fig. 1) appeared invalid since it 
predicted the overall steady state prevalence of IBS in the US. 
population to be 43.6%. Because this prediction was non-realistic, 
Model 1 implied that a given proportion of the population must 
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Figure 1. Irritable bowel syndrome prevalence in general population 
using Model 1 (equal predisposition).
Figure 2. Irritable bowel syndrome (IBS) prevalence in general 
population using Model 2 (assuming that a majority of subjects are 
resistant to the development of IBS).
Figure 3. Irritable bowel syndrome development in a high-risk group 
using Model 3 (active-duty personnel in deployment conditions).
be resistant to the development of IBS. 
Model 2 was the most conservative model derived on existing 
data (Fig. 2). This model was based on an assumption that 90% 
of subjects who develop their first episode of gastroenteritis 
would never develop IBS (at that time and also with any future 
infection). Yet despite these most conservative assumptions, the 
model predicted at steady-state that 9% of the population would 
have developed IBS from an initial episode of acute gastro-
enteritis. This was notable, considering the published prevalence 
of IBS in general. 
In Model 3, the only assumption changed was the incidence 
of acute gastroenteritis to that of troops during deployment (29% 
per month). Figure 3 remarkably demonstrated that this pop-
ulation reached an IBS prevalence of almost 10% after only 12 
months of deployment. This contrasts to the nearly 10 years to 
reach this level in Model 2 of a normal population (Fig. 2). 
Discussion
In this hypothetical examination of the contribution of acute 
gastroenteritis to PI-IBS (and therefore overall IBS), the results 
suggest a significant long term burden of IBS due to acute 
gastroenteritis. This was dependent on assumptions derived from 
published literature. 
Irrespective of assumptions used, each of the proposed models 
has the potential to account for a large number of IBS cases. In 
fact, the most conservative model (Fig. 2) predicts a steady state 
prevalence of IBS of around 9%. This is remarkable, considering 
that the true prevalence of IBS is published to be 10% to 15%.10-15 
These highly theoretical models suggest that PI-IBS could ac-
count for the majority of IBS in the community over time. This 
becomes even more relevant, as increased incidence of IBS is pre-
dicted in populations at higher risk for enteric infection.
Our development of these models is solely intended to sug-
gest a significant impact of acute gastroenteritis in IBS develop-
ment, not to provide exact projections of current and future IBS 
prevalence. As such, certain assumptions may have been overly 
simplified. First, the suggestion that 90% of humans are resistant 
to PI-IBS may be overly conservative, and this may be evidenced 
by increased findings of IBS in military personnel compared to 
predictions with our simple model of varied individual predis-
position to IBS. Second, individuals with repeated enteric in-
fection and also those presenting with fever and bloody stool may 
experience increased risk of IBS development.3,4,16 However, a 
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Salmonella outbreak in Spain demonstrated that uniform infection 
across a population (accounting for varied severity of illness) was 
associated with a 1-year incidence of new IBS of 12%.17 There-
fore, controlling for severity may be unnecessarily complicated. 
In contrast to our simple models of population homogeneity, 
some individuals are subject to certain risk factors and character-
istics which affect the probability of developing acute gastro-
enteritis (and therefore potentially PI-IBS). Individuals who eat 
mostly home-cooked meals, such as those of certain cultures and 
age groups, are less likely to contract acute gastroenteritis. Other 
factors in risk stratification include wealth or religious status, ei-
ther of which increases the likelihood of travel to areas with high 
risk of enteric infection. Finally, the contributions of gut micro-
biota and the mucosal immune system are undoubtedly sig-
nificant but difficult to characterize at present. Certain indivi-
duals may possess a gut flora that can better out-compete a gas-
trointestinal pathogen inoculum and minimize infection severity, 
and others may be able to mount a more robust innate or adaptive 
immune response against infection. Both of these situations 
would decrease the risk of developing PI-IBS in similar fashion 
to the varied disease presentations that can occur following ex-
posure to Clostridium difficile.18 
In conclusion this hypothetical model suggests that PI-IBS 
may account for the majority of IBS. Further studies are needed 
to substantiate the short- and long-term impact of acute gastro-
enteritis on the development of IBS and other functional gastro-
intestinal motility disorders. While the estimates provided by our 
models may be high, if founded, they should prompt serious con-
sideration by policy makers and public health authorities on what 
might be done to mitigate the risk of infectious gastroenteritis 
through improvements in food and water security and communi-
cable disease control.
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